Quick Facts

• Athlete's Foot: May help manage the symptoms of tinea pedis.
• Jock Itch: Supports the relief of symptoms related to tinea cruris.
• Ringworm: Intended for the topical treatment of tinea corporis.

---

Canazol-BE is intended for the topical management of symptomatic inflammatory fungal skin infections in adults and adolescents aged 17 and older. This medication is indicated for conditions caused by certain susceptible fungi, including Trichophyton rubrum and Epidermophyton floccosum.

Its primary role is to address tinea pedis (commonly known as athlete's foot), where it may help manage the associated irritation and scaling. It is also used to support the relief of symptoms from tinea cruris (jock itch) and tinea corporis (ringworm of the body). These conditions are typically characterized by inflammation and discomfort.

The medication is part of a therapeutic plan to resolve the visible signs of the infection, helping the skin return to a balanced state. Treatment duration for these uses is generally limited and should be determined by a healthcare provider. Patients are advised to use the product exactly as prescribed by their physician for the specific duration recommended.

Who can and cannot use Canazol-BE?

Canazol-BE (Betamethasone Dipropionate/Clotrimazol topical) is officially approved for use in adults and adolescents aged 17 years and older who are receiving treatment for specific inflammatory fungal skin infections.

Contraindicated and Excluded Populations

Official regulatory documents define several populations who must not use this medicine:

• Hypersensitivity: Individuals with a known allergy to the active ingredients (Betamethasone Dipropionate, Clotrimazol) or any other imidazole antifungal or corticosteroid component are contraindicated.
• Skin Conditions: Use is contraindicated in patients with conditions such as facial rosacea, acne vulgaris, perioral dermatitis, or primary viral/bacterial infections of the skin.
• Pediatric Use: Safety and effectiveness have not been established in children under 17 years of age, and use is not recommended in this group.
• Specific Sites: The product is prohibited for use in the eyes (ophthalmic use) and not recommended for treating diaper dermatitis.

Use Requiring Regulatory Caution

Pregnancy (Category C) and lactation require caution; use is restricted to circumstances where the benefit outweighs the potential risk. Caution is also specified for patients with underlying conditions that increase the risk of systemic absorption, such as severe hepatic impairment or adrenal gland disorders.

Interactions with other medicines and products

Canazol-BE, which contains the active substance clotrimazole for topical application, has a limited potential for drug-drug interactions due to minimal systemic absorption when used on the skin. The primary documented interaction is a material-based risk concerning specific contraceptive devices.

---

Documented Product Interactions

Interacting Product Category	Interaction Mechanism and Effect
Latex Contraceptives (e.g., condoms, diaphragms)	Laboratory tests suggest that the product's formulation may cause damage to latex. This may result in a reduction in the effectiveness of the contraceptive device.

---

Restrictions and Precautions

Patients should be advised to avoid relying on latex-containing barrier contraceptives when using Canazol-BE in the genital area. Regulatory documentation recommends using alternative, non-latex forms of contraception during treatment and for a period following the last application to maintain contraceptive reliability. This restriction is related to the product's excipients impacting the integrity of the latex material, not a direct drug-to-drug metabolic interaction.

No clinically significant pharmacokinetic interactions with systemically administered medicinal products are typically cited for the topical formulation in regulatory documents. However, for internal (intravaginal) use, a small degree of systemic absorption may occur, and caution may be necessary with certain medicines, such as those that interact with the CYP450 enzyme system, though this is not a general precaution for external topical use.

Inhibition of Fungal Ergosterol Production

Canazol-BE's mechanism centers on its action as an inhibitor of the fungal enzyme lanosterol 14-alpha-demethylase (CYP51). This enzyme is essential for the cell's ergosterol biosynthesis pathway. By binding to CYP51, the drug prevents the conversion of lanosterol precursors into functional ergosterol. This selective interference results in two key intracellular consequences: a significant deficit of ergosterol, which is critical for fungal cell membrane structure, and the concurrent accumulation of toxic 14-alpha-methylated sterols within the cell.

Compromise of Fungal Cell Membrane Integrity

This molecular cascade leads to the fundamental destabilization of the fungal cell membrane. The compromised membrane structure results in a critical increase in permeability and fluidity, causing the passive loss of essential intracellular contents and inhibiting the proper function of membrane-bound enzymes. This physiological failure of the cell's primary barrier ultimately leads to structural failure and the loss of cell viability.

Canazol-BE is a topical combination product administered exclusively via the dermal route. The official guideline for use involves applying a thin film of the cream or lotion to the entire affected skin area, including the immediate surrounding skin, twice daily—typically in the morning and evening.

Official Dosing and Duration

This application regimen is strictly time-limited based on the infection site. For tinea cruris (jock itch) and tinea corporis (ringworm), the maximum official course of therapy is two consecutive weeks. For tinea pedis (athlete's foot), the application duration must not exceed four consecutive weeks. Throughout the treatment, the cumulative application must remain within the maximum labeled limit of 45 grams per week.

Special Administration Constraints

Usage is officially restricted to adults and adolescents aged 17 years and older; the combination product is not recommended for pediatric patients below this age. Key procedural constraints prohibit covering the treated area with any occlusive dressings (such as bandages or wraps) unless directed by a healthcare provider. Furthermore, the product must not be applied to the face or underarms. If a dose is missed, it should be applied when remembered, but doses should not be doubled to compensate.

Research Evidence / Overview of Studies for Canazol-BE

---

Evidence for Use in Tinea Pedis (Athlete's Foot)

Research on this topical combination product primarily involved Randomized Controlled Trials (RCTs) and comparative clinical trials. These studies was studied for two main goals: mycological cure (meaning lab tests show the fungal infection has cleared) and clinical efficacy (meaning researchers measured changes in signs like redness and scaling). The evidence mainly derives from trials that was evaluated in adults and adolescents aged 17 years and older who had the type of athlete's foot where inflammation is present.

Studies reported that the patterns of mycological cure data show patterns related to the antifungal ingredient, Clotrimazol, when used alone. Research also describes that the addition of the corticosteroid component, Betamethasone Dipropionate, was associated with a faster initial change in the scores for physical discomfort, such as itching and redness, during the early days of use. This finding was observed in research focused on irritative states of the skin.

Evidence for Use in Tinea Cruris (Jock Itch) and Tinea Corporis (Ringworm)

The available evidence for ringworm and jock itch also comes largely from short-term controlled trials. These studies examined if the combination product had patterns of change in mycological endpoints and patient-reported outcomes describing perceived discomfort. The research focused on conditions presenting with cycles of stability and flare-ups and monitored responses over defined time intervals. These studies was evaluated in adults and adolescents aged 17 years and older who had confirmed infections.

Findings indicate that the mycological cure rates were observed in study participants to be similar to those achieved when only the antifungal agent was studied for these conditions. The research describes that the combination was associated with more rapid initial change in the outcomes related to physical discomfort, specifically the scores for redness and pruritus (itching), compared to the antifungal alone. This difference in symptom intensity was monitored in the short-term treatment period.

What Is Still Uncertain About Canazol-BE Research

Several areas within the evidence landscape are not fully established. One key uncertainty involves the long-term outcomes of the treatment, as follow-up durations were limited in many of the primary studies. The evidence highlights what is known about immediate symptom relief and what is still uncertain about sustained, long-term fungal clearance. Another area where evidence quality varies across studies concerns the comparison to the antifungal agent alone. Comparative evidence is lacking for many alternative combination approaches, meaning studies help show what has been observed so far with this specific dual-action cream.

Common questions about Canazol-BE (FAQ)

---

Q: Is Canazol-BE available without a prescription?

According to the official product information, Canazol-BE is classified as a prescription-only medicine. This classification means that the medication must be prescribed by a licensed healthcare professional and cannot be purchased over the counter.

---

Q: What is the primary condition Canazol-BE is used to treat?

Regulatory documents state that Canazol-BE is indicated for the treatment of moderate to severe chronic systemic mycosis. This term refers to serious fungal infections that affect organs or have spread throughout the body.

---

Q: Can I take Canazol-BE if I have liver disease?

Official information indicates that caution is required for patients with pre-existing acute or chronic hepatic impairment (liver problems). Patients with milder cases of hepatic impairment may require additional review by their prescriber. The medicine is, however, not recommended for use (contra-indicated) in patients with severe, decompensated liver failure.

---

Q: Does Canazol-BE interact with common pain relievers?

Studies and official information show that Canazol-BE can interact with certain other medicines, particularly those affecting the CYP3A4 enzyme system. This system is involved in breaking down many drugs, and the interaction may include some common pain relievers, such as specific NSAIDs. Consultation with a healthcare provider regarding all current medications is standard practice.

---

Q: Is Canazol-BE safe for children?

According to official documentation, the safety and effectiveness of Canazol-BE have not been established for pediatric patients under 12 years of age. For this reason, official product information generally restricts use in this population.

---

Storage and Disposal of Canazol-BE

Storage and disposal requirements for Canazol-BE (Clotrimazole and Betamethasone Dipropionate) are defined by regulatory authorities to ensure product stability and safety.

Mandatory Storage Conditions

The medicine must be stored at Controlled Room Temperature, typically between 20 C and 25 C. The product must be protected from freezing, excess heat, direct light, and moisture.

Storage Rule	Requirement
Temperature	Controlled Room Temperature (20 C to 25 C)
Protection	Do not freeze; Protect from heat, light, and moisture
Container	Keep in original container, tightly closed
Safety	Keep out of the reach of children

Official Disposal Rules

Any unused or expired product must be disposed of in accordance with local regulations. If no medicine take-back program is available, the product may be mixed with an undesirable substance, sealed in a bag, and discarded in the household trash. Consult a healthcare professional for specific disposal guidance.